Blood–Brain Barrier Dysfunction in Mild Traumatic Brain Injury: Evidence From Preclinical Murine Models

Yingxi Wu†, Haijian Wu†, Xinying Guo†, Brock Pluimer†,3 and Zhen Zhao†,3*

† Center for Neurodegeneration and Regeneration, Zilkha Neurogenetic Institute and Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, ‡ Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, †† Neuroscience Graduate Program, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

Mild traumatic brain injury (mTBI) represents more than 80% of total TBI cases and is a robust environmental risk factor for neurodegenerative diseases including Alzheimer’s disease (AD). Besides direct neuronal injury and neuroinflammation, blood–brain barrier (BBB) dysfunction is also a hallmark event of the pathological cascades after mTBI. However, the vascular link between BBB impairment caused by mTBI and subsequent neurodegeneration remains undefined. In this review, we focus on the preclinical evidence from murine models of BBB dysfunction in mTBI and provide potential mechanistic links between BBB disruption and the development of neurodegenerative diseases.

Keywords: mild traumatic brain injury, blood-brain barrier, murine model, vascular link, neurodegenerative diseases

INTRODUCTION

Traumatic brain injury (TBI) is a leading cause of death and long-term disability around the world (Hackenberg and Unterberg, 2016). Based on the severity, TBI can be classified as mild, moderate, and severe TBI (Chamelian and Feinstein, 2004). As more than 80% of cases are estimated to be mild cases (Rutland-Brown et al., 2006), it is particularly important to understand the pathophysiological mechanisms of mild TBI (mTBI) and develop novel and effective therapeutic approaches. Accumulating evidence has demonstrated that mTBI can result in a series of pathologic events, including neuroinflammation, oxidative stress (Katz et al., 2015), cerebrovascular impairment such as edema, circulatory insufficiency, and blood–brain barrier (BBB) breakdown (Doherty et al., 2016). These events are highly interactive, and all contribute to the long-term cognitive and emotional impairments in mTBI patients (Riggio, 2011).

The BBB is a highly selective membrane that mainly encompasses endothelial cells, sealed by tight junctions, and fortified by pericytes and astrocytic endfeet (Daneman and Prat, 2015). This coordinated network of cells plays an important role in the brain’s physiological homeostasis and functions, while disruption of this network can trigger multiple pathologic events (Zhao et al., 2015). In fact, BBB dysfunction has been increasingly noticed in many neurological conditions of
the central nervous system (CNS), including acute injuries such as TBI and stroke, and chronic neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and chronic traumatic encephalopathy (CTE) (Sweeney et al., 2019). It is worth noting that BBB dysfunction was commonly observed in both mTBI patients and experimental animal models (Sandmark et al., 2019). For instance, histological evidence from human patients indicated that microvascular dysfunction widely occurred from mild to moderate and severe TBI, and not only in the acute and subacute stages after the primary injury but also in the chronic stage in long-term survivors (O’Keeffe et al., 2020). These clinical findings are in general backed up by the evidence from preclinical animal models (Sandmark et al., 2019), which demonstrated that mTBI induces cellular and molecular events at the BBB, including alteration of endothelial transport functions (Villalba et al., 2017), disruption of the crosstalk between endothelial cells and pericytes (Bhowmick et al., 2019), pericyte loss (Zehendner et al., 2015), cerebral blood flow (CBF) reduction, and tissue hypoxia (Han et al., 2020; O’Keeffe et al., 2020). These vascular pathological events interact and evolve with neuroinflammation (Blennow et al., 2012) and contribute to chronic neurodegeneration post-injury.

More importantly, clinical data indicated that BBB impairment can persist for many years and is highly associated with long-term neurological deficits in mTBI patients (Shlosberg et al., 2010). Therefore, it is crucial to evaluate the extent of BBB disruption after mTBI and elucidate the underlying molecular cascades in preclinical models. Such knowledge will not only define a clear vascular link between mTBI and long-term neurological impairments, as well as build up a foundation for developing novel therapeutic approaches. Animal models, more specifically murine models, often closely mimic key neuropathological features in human patients and allow us to study the underlying mechanisms of BBB dysfunction and its associated pathophysiologicals in CNS diseases. Therefore, in this review, we summarize recent evidence in the last 10 years obtained from experimental murine models of mTBI, address the BBB disruptions and its associated pathologic changes in mTBI, and depict the vascular link between mTBI and subsequent neurodegeneration (Figure 1). The criteria used for mTBI (include repetitive mTBI) are mainly based on the recent systematic review (Bodnar et al., 2019). Only studies with histological and/or behavioral validation of mTBI were included to ensure a closer recapitulation of clinical observations under the mTBI category (Bodnar et al., 2019).

**BLOOD–BRAIN BARRIER DYSFUNCTION IN MURINE MODELS OF MILD TRAUMATIC BRAIN INJURY**

Murine models have helped us tremendously to understand the pathogenic events after mTBI, including cerebral microvascular injury and BBB dysfunction. We searched over 6,000 publications related to mTBI on PubMed and found 232 studies potentially covering cerebrovascular impairment and BBB dysfunction (Figure 2). Among them, 17 research articles in the last 10 years were based on murine models of mTBI (Table 1) and selected. The models include not only the well-established weight drop and piston-driven models (Bodnar et al., 2019) but also the increasingly appreciated models including modified controlled cortical impact (CCI), mild blast injury, and fluid percussion (Lifshitz et al., 2016; Bharadwaj et al., 2018). The results were organized by the timing of assessments and mechanism of pathogenesis and discussed in the context of methods used to generate the impact and detection of the vascular impairment.

We surveyed the BBB dysfunction and relevant pathologic changes found in mouse or rat models, covering the acute and subacute stages that evolve within the first 2 weeks after mTBI and the chronic stage that usually takes place 2 weeks after mTBI. The methods commonly used for BBB functional analysis in murine models are (i) histological assessment using plasma proteins such as immunoglobulin G (IgG) and/or exogenous tracers such as Evans blue dye, horseradish peroxidase (HRP), or fluoresce labeled albumin; (ii) in vivo imaging techniques including magnetic resonance imaging (MRI) and multi-photon imaging; and (iii) additional methods such as brain water content

![Figure 1 | Blood–brain barrier (BBB) dysfunction and its associated pathologic events involved in mild traumatic brain injury (mTBI). mTBI can cause a series of pathologic changes including cerebrovascular impairment and BBB dysfunction, neuronal cell death, and axonal damage, as well as neuroinflammation. Also, BBB dysfunction can accelerate the accumulation of pathologic products such as Aβ, tau, and α-synuclein; on the other hand, their deposition around the cerebral vessel has a chronic toxic effect which enhances the BBB disruption and ultimately may lead to neurodegenerative diseases: AD, Alzheimer’s disease; CTE, chronic traumatic encephalopathy; PD, Parkinson’s disease.](image-url)
injury mouse model to investigate the microvascular injury after mTBI. Both Evans blue extravasation and in vivo dynamic MRI of systemically administered gadolinium-based contrast agent confirmed acute and persistent BBB disruption in the ipsilateral cortex of impacted mice. They also examined the postmortem neuropathological changes and did not find the evidence of hemorrhagic contusion, suggesting BBB dysfunction rather than intraparenchymal hemorrhage resulted in permeability changes (Tagge et al., 2018). These data indicate that BBB breakdown occurs within minutes after mTBI; however, it may only be detected by more sensitive methods than classic histological analysis.

The mechanism of the BBB dysfunction after mTBI was also investigated in some of the studies. For example, reduced expression of tight junction protein claudin-5 and BBB disruption were detected in an mTBI model with a blast method, and inhibiting nitric oxide-dependent signaling pathways and preserving tight junction integrity were helpful to maintain BBB integrity after injury (Logsdon et al., 2018). mTBI-induced acute BBB disruption was also associated with microvascular structural damages including swollen astrocyte endfeet and deformation of pericytes in cortical regions 6 h post-injury (Bashir et al., 2020). Using a closed-head TBI model, Tagge et al. (2018) described that mTBI induced capillary retraction, changes in the extracellular matrix and basal lamina, and astrocytic endfoot engorgement, which all contribute to BBB disruption. Interestingly, these vascular structural changes such as loss of tight junctions and pericytes and swollen endfeet (Figure 3, left) are commonly seen in neurodegenerative diseases such as AD, suggesting that a shared underlying mechanism may exist in these distinct pathological conditions.

However, five recent studies found no evident BBB disruption after mTBI (Table 1). For example, Kane et al. (2012) found mild astrocytic activation but lack of BBB disruption to IgG or edema in weight drop model of mTBI in mice, while Whalen’s group reported that the BBB integrity was not compromised after single or repetitive closed head injury by immunohistochemical analysis of Evans blue or intracerebral levels of mouse IgG (Meehan et al., 2012; Chung et al., 2019; Wu et al., 2019). In a long-term study, Lynch et al. (2016) also found no BBB leakage to Evans blue at 7 months after repetitive midline mTBI, despite vascular abnormality still existed at that time. These different results may reflect the differences in animal models, methodology in detecting BBB changes, and observation time points.

**BLOOD–BRAIN BARRIER DYSFUNCTION IN THE CHRONIC STAGE OF MILD TRAUMATIC BRAIN INJURY**

In addition to its breakdown during the acute and subacute phases of mTBI, the pathological changes of BBB integrity in the chronic phase of mTBI have been well documented in human patients, yet underexplored in animal models (Jullienne et al., 2016; Sandmark et al., 2019). For example, Tomkins et al. (2011) found that 13 of 27 mTBI patients showed parenchymal regions with BBB disruption based on MRI scans, which were...
| Study                  | Animal | Model                  | BBB Impairment                                | Neuropathology                                      | Neuroinflammation                              | Motor function                              | Cognitive function                          |
|-----------------------|--------|------------------------|------------------------------------------------|----------------------------------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------|
| Yang et al., 2013     | Mouse  | Weight drop            | BBB disruption detected by Lucifer yellow and FITC-albumin at 1.5–6 h | Increased expression of serum NSE at 1.5–6 h, 1 day | Increased expression of brain MDC and MIP-1α on 1 day | Deficit in rotarod test on 1–5 days       | Impairment (NOR: 1–4 days)                  |
| Chen et al., 2014     | Mouse  | Modified CCI           | BBB disruption detected by Evan blue at 1 h   | Axonal injury on 1 day; Increased neuronal degeneration on 1–8 days | Activation of astrocytes and microglia on 8 days | Deficit in rotarod test on 1–3 days       | No impairment (SOR and contextual fear conditioning: 5–8 days) |
| Gama Sosa et al., 2014| Rat    | Blast exposure; RHI    | Altered microvascular ECM, microvascular occlusion and degeneration, intraventricular hemorrhage at 6–10 months | n/a | Activation of astrocytes in 10 months | n/a | n/a |
| Katz et al., 2015     | Rat    | LFP                    | BBB disruption detected by Evan blue at 24 h   | n/a | Activation of astrocytes at 24 h | Cytokine upregulation at 24 h | n/a | Impairment in NBS and NSS tests at 2–24 h |
| Li et al., 2016       | Mouse  | Micro TBI compression  | BBB disruption detected by rhodamine B at 5–60 min | Increased cell death at 6–24 h | n/a | n/a | n/a |
| Logsdon et al., 2018  | Mouse  | Blast exposure; RHI    | BBB disruption detected by 14C-sucrose and 99mTc-albumin at 0.25 h, 3 days | n/a | Activation of astrocytes and microglia on 3 days | n/a | n/a |
| Adams et al., 2018    | Mouse  | CHI; RHI               | Decreased CBF and CVR detected by MRI on 14 days | Reduced evoked neuronal responses without changes in neuronal density on 14 days | Activation of astrocytes on 14 days | n/a | n/a |
| Bharadwaj et al., 2018| Mouse  | MFP                    | BBB disruption detected by HRP staining and nanoparticles at 3 h | n/a | n/a | n/a | n/a |
| Tagge et al., 2018    | Mouse  | Lateral CHI            | BBB disruption detected by Evans blue, extravasated serum albumin, and DCE-MRI at 24 h | Neuronal damage on 1 day; Decreased neuronal density on 3–14 days | Activation of astrocytes and microglia on 1–3 days | Transient impairments in neurobehavioral response tests | n/a |
TABLE 1 | Continued

| Study                  | Animal                  | Model   | BBB Impairment                                                                 | Neuropathology        | Neuroinflammation | Motor function               | Cognitive function   |
|------------------------|-------------------------|---------|--------------------------------------------------------------------------------|-----------------------|-------------------|-------------------------------|----------------------|
| Wendel et al., 2018    | Mouse (juvenile)         | CHI     | Increased vessel density and length detected by IHC on 4–60 days               | White matter disruption on 4–14 days | r/a               | n/a                           | n/a                  |
| Yates et al., 2017     | Rat                     | Weight drop; RHI | BBB disruption detected by Evan blue on 3 days                                   | n/a                   | No activation of astrocytes and microglia on 4 days | Deficit in Foot-fault test on 1 day | Impairment in MWM on 4 days |
| Ichkova et al., 2020   | Mouse (juvenile)         | CHI     | BBB disruption and altered cortical cerebrovascular reactivity detected by IgG staining on 1–3 days | Axonal pathology on 30 days; No neuronal loss on 1, 3, 7, 30 days | n/a               | n/a                           | Deficit in open-field test on 1–30 days |
| Kane et al., 2012      | Mouse                   | Weight drop; RHI | No BBB disruption by IgG staining on 7 days                                      | n/a                   | Mild activation of astrocytes on 7 days       | Deficit in rotarod test on 1 day and locomotor activity on 5 days | n/a                  |
| Meehan et al., 2012    | Mouse                   | Weight drop; RHI | No BBB disruption by IgG staining at 1 h, 24 h                                  | No changes in neuronal degeneration and axonal injury at 1 h, 24 h | n/a               | n/a                           | Impairment in MWM at 1 month |
| Lynch et al., 2016     | Mouse (aged)            | CHI; RHI | No BBB disruption by S100g or occludin at 7 months                              | n/a                   | Activation of astrocytes and microglia in the CC | n/a                           | Spatial memory deficits in Barnes Maze task at 1–6 months |
| Chung et al., 2019     | Mouse                   | CHI     | No BBB disruption by IgG staining at 24 h                                       | No changes in neuronal degeneration at 24 h, 48 h | Increased infiltration of CD11b⁺/CD45⁺ leukocytes at 72 h | No deficit in Foot-fault test on 1–14 days | Impairment in MWM on 3–42 days |
| Wu et al., 2019        | Mouse (adolescent)      | CHI; RHI | No BBB disruption by Evan blue at 4 h                                           | No changes in neuronal degeneration at 1 year | No activation of astrocytes and microglia at 4 h–1 year | n/a                           | Impairment in MWM on 7 days–9 months |

BBB, blood–brain barrier; CBF, cerebral blood flow; CC, corpus callosum; CCI, controlled cortical impact; CHI, closed head injury; CVR, cerebrovascular reactivity; DCE-MRI, dynamic contrast-enhanced MRI; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; HRP, horseradish peroxidase; IHC, immunohistochemistry; LFP, lateral fluid percussion; MDC, macrophage-derived chemokine; MFP, midline fluid percussion; MIP-1α, macrophage inflammatory protein-1α; MRI, magnetic resonance imaging; mTBI, mild traumatic brain injury; MWM, Morris water maze; NSS, neurological severity scores; NOR, novel object recognition; NSE, neuron-specific enolase; RHI, repetitive head injury; SOR, spatial object recognition.
identified up to a median of 2.5 months after the initial trauma event, indicating that lasting BBB disruption exists in nearly half of the mTBI patients. In a different cohort of 17 mTBI patients with post-concussion syndromes (PCSs), eight of them exhibited abnormal BBB permeability based on single-photon emission computed tomography (SPECT) of $^{99m}$Tc-diethylenetriaminepentaacetic acid radiotracer (Korn et al., 2005). These patients were scanned between 1 month and 7 years after their respective head injuries. More recently, Yoo et al. (2019) demonstrated that mTBI patients with PCS, who had a median of 4-month time interval between injury and MRI examinations, exhibited much higher BBB permeability based on $K_{\text{trans}}$ measurement from dynamic contrast-enhanced MRI (DCE-MRI) when compared with controls. Similar situations were also reported from patients diagnosed with concussion in adolescent sports (O’Keefe et al., 2020) and football players (Weissberg et al., 2014).

Consistent with observations in human patients, cerebrovascular dysfunction was detected in a repeated mTBI mouse model at 2 weeks after the insult (Adams et al., 2018). Functional assessments revealed that repeated impacts cause sustained decreases of CBF and cerebrovascular reactivity, along with neuronal function deficits and astrogliosis in peri-contusion areas (Adams et al., 2018). In addition, mTBI can elicit an early and long-lasting cerebrovascular dysfunction in juvenile mice (Wendel et al., 2018; Ichkova et al., 2020), accompanied by astrocyte response and gliovascular changes (Rodriguez-Grané et al., 2018; Clément et al., 2020). Furthermore, pediatric mTBI can morphologically alter the vasculature of the ipsilateral corpus callosum differentially between the acute/subacute stage and the chronic stage (Wendel et al., 2018). As demonstrated, mTBI induced an initial increase in vessel parameters (e.g., vessel density and length) at 4 days post-injury (DPI), which was followed by a transient decrease at 14 DPI but with a subsequent increase in vessel density at 60 DPI (Wendel et al., 2018). It suggested that these microvascular alterations contribute to the long-term reorganization of the ipsilateral corpus callosum after mTBI (Wendel et al., 2018). Finally, chronic changes

---

**FIGURE 3** | Blood-brain barrier (BBB) dysfunction in the acute/subacute stage (Left) and chronic stage (Right) of mild traumatic brain injury (mTBI). In the acute/subacute stage, mTBI induces the endothelial cell (EC) death, loss of pericytes and tight junction proteins, astrocytic endfeet swelling, as well as basement membrane damage and ultimately an impairment of BBB permeability. In the chronic stage, mTBI causes BBB leakage and influx of neurotoxic blood-derived proteins and cells into the brain parenchyma, which can induce gliosis and misfolded protein accumulation post-insult; mTBI-induced clearance deficiency of BBB promotes misfolded protein accumulation.
in the microvasculature were also reported in rats several months after the initial blast exposure (Gama Sosa et al., 2014). In particular, intraventricular hemorrhage was observed in four out of 23 blast-exposed animals examined between 6 and 10 months after the last blast exposure, which may be attributed to continued vascular fragility within the choroid plexus post-injury (Gama Sosa et al., 2014). As suggested, blast exposure may induce the degradation and remodeling of the extracellular matrix, which contributes to chronic microvascular pathology after injury (Gama Sosa et al., 2014). Due to the limited number of reports, the potential molecular and cellular mechanisms of BBB dysfunction in the chronic phase of murine mTBI remain largely unknown. Abnormal expressions of junctional proteins and matrix metalloproteinases may potentially involve the degradation of the extracellular matrix and prolonged BBB breakdown, and chronic inflammation may also play a crucial role. More importantly, the crosstalk between vascular impairment and neuroinflammation in the context of persistent BBB dysfunction after mTBI is yet to be determined (Figure 3, right).

**BLOOD–BRAIN BARRIER DYSFUNCTION OF MILD TRAUMATIC BRAIN INJURY MODEL IN THE HIGH-THROUGHPUT SEQUENCING ERA**

Over the past decade, high-throughput sequencing methods have revolutionized the entire field of biology. The RNA sequencing to study the entire transcriptomes in detail has driven many important discoveries for various neurological disorders (von Gerthten et al., 2005; Redell et al., 2013; Lipponen et al., 2016; Meng et al., 2017). The brain microvascular endothelial cells are the major component of the BBB and play critical roles to maintain its normal function and integrity. Therefore, understanding endothelial cell-specific transcriptional profiles can help us to identify novel mechanisms of TBI-induced changes within the BBB. As most of the previous genomic profiling studies of TBI are based on heterogeneous mixtures of brain cell types, Munji et al. (2019) recently used endothelial cell enrichment for deep RNA sequencing to decipher the transcriptome differences at 24 h (acute), 72 h (subacute), and 1 month (chronic) after TBI in mice. They found that most unique and dramatic changes were at the acute time point, whereas few overlapped genes were observed between acute and chronic periods. These findings reflect the severity of the initial insult on the endothelial functions and BBB integrity and immediate response at the early stage, yet clearly point out to the distinct molecular mechanisms that are involved in acute/subacute and chronic phases of TBI. In addition, they also found that the synthesis of extracellular matrix molecules and activation of proteases further contributed to the BBB changes in the acute and subacute period. On the other hand, the immune response may play a more prominent role in the chronic period. These findings provided us further directions for investigating the endothelial dysfunction in TBI.

The diversity of cell types at the BBB (Vanlandewijck et al., 2018), only focusing on endothelial cells, will mask crucial signals from other BBB-related cell types. Therefore, single-cell RNA sequencing represents an approach to overcome this problem. Arneson et al. (2018) firstly investigated the mTBI pathogenesis in thousands of individual brain cells in parallel using single-cell RNA sequencing. Unsupervised clustering analysis identified BBB-associated cell types such as endothelial cells and mural cells. Besides, they also found a previously unknown cell type after mTBI, which likely is a migrating endothelial cell, as it carries key signatures of cell growth and migration as well as endothelial identity. This is consistent with previous research that endothelial cell is a main component of BBB that is destroyed after mTBI (Shlosberg et al., 2010), and the proliferation and migration of endothelial cells are inherent aspects of neovascularization after injuries (Salehi et al., 2017). More importantly, pathway analysis informed by genes with significant changes from both endothelial cells and astrocytes implicates endoplasmic reticulum dysfunction after mTBI. As endoplasmic reticulum stress is a key contributor to the injury-induced neurodegeneration (Oakes and Papa, 2015), the single-cell RNA sequencing data indicated that endoplasmic reticulum dysfunction in BBB may be an overlooked mechanism in mTBI. In addition, their data also demonstrated that cellular interactions based on extracellular matrix of endothelial cells are also heavily impacted after mTBI (Arneson et al., 2018), which is consistent with a recent report (Munji et al., 2019). Taken together, deep RNA sequencing and single-cell RNA sequencing data have become valuable resources to explore BBB dysfunction in mTBI, which will likely bring new insights to the true mechanism of vascular impairment after mTBI.

**BLOOD–BRAIN BARRIER DYSFUNCTION AND NEUROINFLAMMATION IN MILD TRAUMATIC BRAIN INJURY**

In animal models of mTBI, BBB dysfunction is closely associated with neuroinflammation in both acute/subacute stage and chronic period. In the event of mTBI, the tight junction complexes and basement membrane are disrupted, which results in increased permeability of BBB and inflammatory response after injury (Chodobski et al., 2011). Activation of microglia, stimulation of astrocytes, and neuronal cell death are closely associated with neurodegeneration after mTBI (Ramos-Cejudo et al., 2018; Figure 1). Notably, many studies reported that microglia and astrocytes are activated in the acute period after mTBI. For example, in a lateral impact of closed head injury mouse model, Tagge et al. (2018) reported that activated microglia and reactive astrocytes were detected at 24 h post-injury in the ipsilateral cortex, which peaked around 3 DPI and started to be resolved in 2 weeks, although perivascular accumulation of hemosiderin-laden macrophages may persist.

Limited evidence has indicated that BBB dysfunction precedes gliosis and neuroinflammation at least in murine models of mTBI. For example, Huh et al. (2008) showed that BBB disruption in their midline CCI rat model of mTBI occurs within
injury (Baker and Patel, 2000). There are growing interests to investigate the acute/subacute and long-term pathologic changes after mTBI, as well as a focus on motor and cognitive impairments. In this study, we collected preclinical evidence from murine models to describe the role of BBB dysfunction in mTBI. BBB plays a key role in maintaining brain function stability, the integrity of BBB may be compromised under pathologic conditions such as TBI, stroke, brain tumor, and AD (Sweeney et al., 2019). For example, previous research showed BBB leakage was detected in a stroke model of rat (Michalski et al., 2010). In our review, we included 17 representative studies that described the BBB breakdown after mTBI. Twelve of them reported that the BBB was compromised after mTBI; however, five studies indicated that BBB breakdown was not detected in mTBI, even in receptive mTBI models. Up to now, it is still unclear whether the minor discrepancy was a result of the differences in mTBI animal models, animal ages, procedures, time points of observation, or methodology.

Mechanistically, impairment of BBB can initiate a series of adverse events, including the leakage of serum-derived circulating agents into the brain parenchyma and improper activation of signaling pathways (Manev, 2009). As some studies indicated that mTBI can induce sustained shear stress located within the impact zone, capillary retraction, pericyte degeneration, and astrocytic endfeet swelling, which all contribute to microvascular injury and BBB breakdown post-insult (Tagge et al., 2018), the exact mechanism of BBB impairment in different models of mTBI could still vary and depend on the severity. Importantly, emerging evidence from human genome-wide association studies suggests that many signature genes and network regulators of TBI may be associated with neurological disorders, which could be used as elements of prognosis and plausible interventional targets for TBI (Meng et al., 2017). Single-cell molecular alterations were reported after mTBI by using unbiased single-cell sequencing, which provides new insights to the molecular pathway mechanism and therapeutics in mTBI and its related neurodegeneration (Arneson et al., 2018).

Mild traumatic brain injury is considered a long-term risk for neurobehavioral changes, cognitive decline, and neurodegenerative disease including AD (McAllister and McCrea, 2017). Cognitive and motor function changes commonly occur after mTBI and may have lifelong consequences, which are still difficult to detect and trace in clinical settings. On the other hand, murine animal models of mTBI provide us quantitative measures and longitudinal follow-ups. Most used methods for motor function tests include Foot-fault, rotarod, and beam walking assays, and cognitive function tests include nest construction, food burrowing, novel object recognition, fear conditioning, MWM, etc. In our review, we found that most studies reported the motor deficit and cognitive impairment after mTBI range from 1 day to several months. However, few studies indicated the absence of motor or cognitive function impairment, which may be due to differences in animal models or procedures as described above. Vascular dysfunction and BBB breakdown are associated with cognitive impairments in aging and neurodegenerative diseases such as AD.
(Iadecola, 2004). In the mTBI event, cerebrovascular dysfunction can result in circulatory insufficiency and cause neuronal dysfunction (Jullienne et al., 2016). Edema formation and BBB breakdown after mTBI can also disturb the brain homeostasis and the clearance of toxic products such as β-amyloid, which will accelerate the neuronal damage and contribute to the mTBI-associated late-life neurodegeneration. Can we target vascular dysfunctions in mTBI as a potential therapeutic intervention? Histological and genetic profiling evidence has indicated changes in different BBB modalities after mTBI (Meng et al., 2017; Arneson et al., 2018; Munji et al., 2019; Sandmark et al., 2019), including alteration of extracellular matrix and basement membrane, metalloproteinase, etc. Targeting these endophenotypes may offer novel therapeutic opportunities. But the journey is still out there.

CONCLUSION

In this review, we focused on BBB dysfunction after mTBI in murine models and found that BBB breakdown and microvascular impairment are important pathological mechanisms for cognitive impairment after mTBI. Restoring vascular functions might be beneficial for patients with mTBI and reduce the risk of developing cognitive impairments post-insult.

AUTHOR CONTRIBUTIONS

ZZ and YW designed the review outline, wrote and reviewed the review, did the literature search, and data extraction and interpretation. HW, XG, and BP provided critical reviews, revised the manuscript, and provided relevant insights and edits. All authors read and approved the final version of the manuscript.

FUNDING

The work of ZZ is supported by the National Institutes of Health (NIH) grant nos. R01AG061288, R01NS110687, R03AG063287, and R21AG066090; Department of Defense (DOD) grant AZ190072; and Bright Focus Foundation grant A2019218S.
blood-brain barrier disruption in mild traumatic brain injury patients with post-concussion syndrome. *Eur. Radiol.* 29, 1308–1317. doi: 10.1007/s00330-018-5656-z

Zehendner, C. M., Sebastiani, A., Hugonnet, A., Bischoff, F., Luhmann, H. J., and Thal, S. C. (2015). Traumatic brain injury results in rapid pericyte loss followed by reactive pericytosis in the cerebral cortex. *Sci. Rep.* 5:13497. doi: 10.1038/srep13497

Zhao, Z., Nelson, A. R., Betsholtz, C., and Zlokovic, B. V. (2015). Establishment and dysfunction of the blood-brain barrier. *Cell* 163, 1064–1078. doi: 10.1016/j.cell.2015.10.067

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wu, Wu, Guo, Pluimer and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.